- Home
- GHG vs AVIR Comparison
GHG vs AVIR Comparison
Compare GHG & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- AVIR
- Stock Information
- Founded
- GHG 2004
- AVIR 2012
- Country
- GHG China
- AVIR United States
- Employees
- GHG N/A
- AVIR N/A
- Industry
- GHG Hotels/Resorts
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- GHG Consumer Discretionary
- AVIR Health Care
- Exchange
- GHG Nasdaq
- AVIR Nasdaq
- Market Cap
- GHG 259.8M
- AVIR 247.5M
- IPO Year
- GHG 2018
- AVIR 2020
- Fundamental
- Price
- GHG $2.50
- AVIR $3.25
- Analyst Decision
- GHG
- AVIR Hold
- Analyst Count
- GHG 0
- AVIR 1
- Target Price
- GHG N/A
- AVIR $6.88
- AVG Volume (30 Days)
- GHG 13.0K
- AVIR 503.8K
- Earning Date
- GHG 02-25-2025
- AVIR 11-07-2024
- Dividend Yield
- GHG 4.00%
- AVIR N/A
- EPS Growth
- GHG N/A
- AVIR N/A
- EPS
- GHG 0.28
- AVIR N/A
- Revenue
- GHG $201,166,731.00
- AVIR N/A
- Revenue This Year
- GHG N/A
- AVIR N/A
- Revenue Next Year
- GHG $8.78
- AVIR N/A
- P/E Ratio
- GHG $8.99
- AVIR N/A
- Revenue Growth
- GHG N/A
- AVIR N/A
- 52 Week Low
- GHG $2.31
- AVIR $2.75
- 52 Week High
- GHG $4.10
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- GHG 41.31
- AVIR 53.42
- Support Level
- GHG $2.39
- AVIR $3.10
- Resistance Level
- GHG $2.71
- AVIR $3.32
- Average True Range (ATR)
- GHG 0.10
- AVIR 0.15
- MACD
- GHG -0.01
- AVIR 0.03
- Stochastic Oscillator
- GHG 26.83
- AVIR 88.50
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).